


The Challenge

Now more than ever, scientists understand that diseases are population-specific. To support this research, biobanks must increase the variety and number of samples they store. Unfortunately, with more samples come more sample identification errors.

98% of errors happen **before** a sample even reaches a biobank.




39% of cancer researchers reported difficulty obtaining biospecimens of **adequate number**

47% of cancer researchers reported difficulty obtaining biospecimens of **adequate quality**

22,882,299

Total number of **banked samples in Europe**, according to the BBMRI catalog.



Pie Chart: Total sample per type (millions). "Other" includes bodily fluids, stool, and pathogens.

The Movement

Facing a history of sample ID errors, leading biobanks are making high-quality samples a standard. Better quality samples lead to better data, outcomes, and reproducibility—translating into more grant renewals for researchers and re-engagement of the biobank.

DOWNLOAD the *Evolution of Biobanking* White paper: www.fluidigm.com/quality

MAKE YOUR BIOBANK
A **QUALITY** RESEARCH PARTNER

Fluidigm 

+1 866 359 4354 | FLUIDIGM.COM/QUALITY